ATE258797T1 - Verwendung von amifostin - Google Patents
Verwendung von amifostinInfo
- Publication number
- ATE258797T1 ATE258797T1 AT98906688T AT98906688T ATE258797T1 AT E258797 T1 ATE258797 T1 AT E258797T1 AT 98906688 T AT98906688 T AT 98906688T AT 98906688 T AT98906688 T AT 98906688T AT E258797 T1 ATE258797 T1 AT E258797T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- aminoalkyl
- amifostine
- adverse
- patients
- Prior art date
Links
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 title 1
- 229960001097 amifostine Drugs 0.000 title 1
- -1 aminoalkyl phosphorothioate Chemical compound 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Insulating Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/798,840 US6051563A (en) | 1997-02-12 | 1997-02-12 | Methods for the administration of amifostine and related compounds |
| PCT/US1998/003614 WO1998034622A1 (en) | 1997-02-12 | 1998-02-11 | Methods for the administration of amifostine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE258797T1 true ATE258797T1 (de) | 2004-02-15 |
Family
ID=25174410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98906688T ATE258797T1 (de) | 1997-02-12 | 1998-02-11 | Verwendung von amifostin |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6051563A (de) |
| EP (1) | EP1007055B1 (de) |
| JP (1) | JP2001512447A (de) |
| AT (1) | ATE258797T1 (de) |
| AU (1) | AU750591B2 (de) |
| CA (2) | CA2280773C (de) |
| DE (1) | DE69821498T2 (de) |
| DK (1) | DK1007055T3 (de) |
| ES (1) | ES2216271T3 (de) |
| PT (1) | PT1007055E (de) |
| WO (1) | WO1998034622A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6051563A (en) * | 1997-02-12 | 2000-04-18 | U.S. Bioscience, Inc. | Methods for the administration of amifostine and related compounds |
| US6573253B2 (en) * | 1997-02-12 | 2003-06-03 | Medimmune Oncology Inc. | Methods for the administration of amifostine and related compounds |
| US5994409A (en) * | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
| US6239119B1 (en) * | 1998-04-27 | 2001-05-29 | Medimmune Oncology, Inc. | Topical administration of amifostine and related compounds |
| US6407278B2 (en) | 1998-11-16 | 2002-06-18 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and methods for the preparation and use of the same |
| US6384259B1 (en) | 1998-11-16 | 2002-05-07 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and dosage form |
| IL152433A0 (en) * | 2000-04-26 | 2003-05-29 | Univ Oregon Health Sciences | Administration of a thiol-based chemoprotectant compound |
| US7053072B2 (en) * | 2001-05-11 | 2006-05-30 | Medimmune Oncology, Inc. | Methods for the administration of amifostine and related compounds |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| AU2003230691A1 (en) * | 2002-03-20 | 2003-10-08 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| US7629333B2 (en) | 2002-03-29 | 2009-12-08 | Medimmune, Llc | Stable amorphous amifostine compositions and methods for the preparation and use of same |
| EP1809272A4 (de) * | 2004-10-18 | 2008-01-02 | Maroon Biotech Corp | Verfahren und zusammensetzungen zur behandlung von schäden durch freie radikale |
| JP6163304B2 (ja) * | 2009-07-15 | 2017-07-12 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法 |
| CN103336902B (zh) * | 2013-06-27 | 2016-01-13 | 西安交通大学 | 一种基于模拟分布平衡血药浓度的药物绝对生物利用度检测方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3892824A (en) * | 1968-12-16 | 1975-07-01 | Southern Res Inst | S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates |
| EP0409845A4 (en) * | 1988-02-23 | 1991-07-03 | U.S. Bioscience | Method for protection from chemotherapeutic side effects |
| US5424471A (en) * | 1992-07-31 | 1995-06-13 | U.S. Bioscience, Inc. | Crystalline amifostine compositions and methods of the preparation and use of same |
| SG47101A1 (en) | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
| JPH06192109A (ja) * | 1992-09-04 | 1994-07-12 | Fuji Kagaku Kogyo Kk | 抗腫瘍効果増強剤 |
| DE69526395D1 (de) * | 1994-08-13 | 2002-05-23 | Roche Diagnostics Gmbh | Verwendung von Interferon-gamma zur Vermeidung der Proliferation und Differenzierung der primitiven Hämapoietischen Vorläuferzellen |
| US5846958A (en) * | 1995-02-17 | 1998-12-08 | U.S. Bioscience, Inc. | Methods of using aminothiols to promote hematopoietic progenitor cell growth |
| US6051563A (en) * | 1997-02-12 | 2000-04-18 | U.S. Bioscience, Inc. | Methods for the administration of amifostine and related compounds |
-
1997
- 1997-02-12 US US08/798,840 patent/US6051563A/en not_active Expired - Lifetime
-
1998
- 1998-02-10 US US09/021,139 patent/US6127351A/en not_active Expired - Lifetime
- 1998-02-11 WO PCT/US1998/003614 patent/WO1998034622A1/en not_active Ceased
- 1998-02-11 JP JP53511398A patent/JP2001512447A/ja active Pending
- 1998-02-11 AT AT98906688T patent/ATE258797T1/de active
- 1998-02-11 DK DK98906688T patent/DK1007055T3/da active
- 1998-02-11 PT PT98906688T patent/PT1007055E/pt unknown
- 1998-02-11 DE DE69821498T patent/DE69821498T2/de not_active Expired - Lifetime
- 1998-02-11 EP EP98906688A patent/EP1007055B1/de not_active Expired - Lifetime
- 1998-02-11 AU AU61849/98A patent/AU750591B2/en not_active Expired
- 1998-02-11 CA CA002280773A patent/CA2280773C/en not_active Expired - Fee Related
- 1998-02-11 ES ES98906688T patent/ES2216271T3/es not_active Expired - Lifetime
- 1998-02-11 CA CA002625727A patent/CA2625727A1/en not_active Abandoned
-
2000
- 2000-06-05 US US09/586,753 patent/US6218377B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1007055A1 (de) | 2000-06-14 |
| DK1007055T3 (da) | 2004-06-07 |
| CA2280773A1 (en) | 1998-08-13 |
| JP2001512447A (ja) | 2001-08-21 |
| CA2280773C (en) | 2008-07-22 |
| US6051563A (en) | 2000-04-18 |
| ES2216271T3 (es) | 2004-10-16 |
| WO1998034622A1 (en) | 1998-08-13 |
| AU750591B2 (en) | 2002-07-25 |
| PT1007055E (pt) | 2004-06-30 |
| DE69821498T2 (de) | 2004-12-02 |
| AU6184998A (en) | 1998-08-26 |
| EP1007055B1 (de) | 2004-02-04 |
| US6127351A (en) | 2000-10-03 |
| CA2625727A1 (en) | 1998-08-13 |
| US6218377B1 (en) | 2001-04-17 |
| DE69821498D1 (de) | 2004-03-11 |
| EP1007055A4 (de) | 2002-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69821498D1 (de) | Verwendung von amifostin | |
| EP1537861A3 (de) | Verwendung von Aminothiolverbindungen zur Behandlung von Xerostomie, verursacht durch therapeutische Mittel oder Bestrahlung | |
| ATE239474T1 (de) | Verwendung von levobupivacain | |
| NO20014415D0 (no) | Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens | |
| GR3006001T3 (de) | ||
| MXPA03003960A (es) | Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos. | |
| NZ516349A (en) | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease | |
| DE60120761D1 (de) | Hämodiafiltration/hämofiltrations-patronen | |
| DE69617729D1 (de) | Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom | |
| ATE372774T1 (de) | Medikament zur verabreichung von amifostin und verwandten wirkstoffen | |
| BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
| ATE225177T1 (de) | Verwendung von (+)mefloquine zur behandlung von malaria | |
| HU911193D0 (en) | Conjugates consisting of difluor-glutaminic acid and pholates as well as antipholates being suitable for treating pneosplastic illnesses | |
| TR199802200A2 (xx) | S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi. | |
| DE69018099D1 (de) | Polyamin-Derivate als antineoplastische Mittel. | |
| MD1140C2 (ro) | Remediu cu acţiune regenerativă şi citoprotectoare | |
| DE69720064D1 (de) | Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen | |
| DE60006284D1 (de) | Arzneimittel zur behandlung konvulsivischer zustände | |
| TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. | |
| DK0458537T3 (da) | Anvendelse af en terapeutisk forbindelse til behandling af bronkitis | |
| ATE72115T1 (de) | Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a- | |
| AU2444695A (en) | Use of intravenously administered iron in the therapy of tumoral and infectious diseases | |
| IT9048106A0 (it) | Associazione medicamentosa per il trattamento dell'ipertensione e dell'insufficienza cardiaca congestiva. (caso 100-7516) | |
| UA10754A (uk) | Спосіб лікуваhhя артеріальhих гіпертеhзій різhого геhезу | |
| ES2166778T3 (es) | Factor de crecimiento ii de tipo insulina como agente antitumoral. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1007055 Country of ref document: EP |